Despite the general relationship between CD133 and breast tumor malignancy, some controversies concern the significance of CD133 in tumors with a triple negative phenotype (TNBC), in which CD133 is strongly hypomethylated with respect to other breast cancer subtypes [27]. The gene discussed is PROM1; the disease is breast carcinoma.